DOP072: Association of ustekinumab trough concentrations with clinical, biochemical and endoscopic outcomesECCO'16 DOP
2016
1
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panelECCO'16 DOP
2016
1
DOP076: A Danish cross-sectional study: Autoimmune and chronic inflammatory disorders associated with Ulcerative Colitis.ECCO'16 DOP
2016
1
DOP077: Immunochip Analysis Identifies Multiple Susceptibility Loci for Collagenous ColitisECCO'16 DOP
2016
1
DOP078: Risk of malignancy in paediatric inflammatory bowel disease: Results from the DEVELOP registryECCO'16 DOP
2016
1
DOP079: Predictors of first neoplastic colonic lesion in patients with inflammatory bowel disease undergoing colonoscopic surveillanceECCO'16 DOP
2016
1
DOP081: Outcomes of Colitis-Associated Dysplasia after Referral from the Community to a Tertiary CenterECCO'16 DOP
2016
1
DOP082: PEA immunoassay technology identifies novel serum biomarkers that can diagnose and classify Inflammatory Bowel Diseases: IBD Character ConsortiumECCO'16 DOP
2016
1
DOP083: Fecal calprotectin improves the predictive power of 3 practical indices for mucosal healing among patients with Crohn’s disease: results from PREDICTECCO'16 DOP
2016
1
DOP084: Identification of a potential new prognostic biomarker to select IBD patients that fail standard therapyECCO'16 DOP
2016
1
DOP085: Ileocolonic Involvement and Diagnosis is Related to Fragments of the Extracellular Matrix Measured in Serum of Patients with Crohn’s Disease.ECCO'16 DOP
2016
1
DOP088: Inflammatory biomarkers in serum discriminate Crohn’s disease and ulcerative colitis from healthy controlsECCO'16 DOP
2016
1
DOP089: Microbiota profiles in treatment naïve Norwegian IBD and non-IBD patients. Part of the EU IBD character consortiumECCO'16 DOP
2016
1